Ipamorelin vs CJC-1295: Evidence & Australian Regulatory Status
These compounds have distinct regulatory and evidence considerations. A comparison does not recommend a treatment, establish suitability or predict outcomes.
Ipamorelin vs CJC-1295 — head to head
| Attribute | Ipamorelin | CJC-1295 |
|---|---|---|
| Class | Synthetic pentadecapeptide | Thymosin-associated research compound |
| Human evidence | Limited human evidence; mostly preclinical studies | Full protein and fragment findings are not interchangeable |
| Human evidence | Limited human evidence; mostly preclinical studies | Full protein and fragment findings are not interchangeable |
| Human evidence | Limited human evidence; mostly preclinical studies | Full protein and fragment findings are not interchangeable |
| AU legal pathway | The registered doctor decides whether any clinical step is appropriate. | The registered doctor decides whether any clinical step is appropriate. |
Verdict
Evidence limitations and individual safety require clinical assessment. Registration and lawful supply must be checked; this information is not a treatment recommendation.
Frequently asked questions
- What safety and evidence questions need assessment?
- Relevant questions include the quality of human studies, possible interactions, medical conditions that affect risk and gaps in long-term safety information.
- Is the CJC-1295 + Ipamorelin blend legal in Australia?
- The registered doctor decides whether any clinical step is appropriate.
Read the full profiles
Regulatory status
Ipamorelin
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Regulatory status
CJC-1295 + Ipamorelin
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Other comparisons
Questions about clinical assessment
Questions about whether any treatment is right for you should be discussed with a registered doctor.
How Australian access pathways work All peptides